56 related articles for article (PubMed ID: 31746425)
1. A FXYD5/TGF‑β/SMAD positive feedback loop drives epithelial‑to‑mesenchymal transition and promotes tumor growth and metastasis in ovarian cancer.
Bai Y; Li LD; Li J; Chen RF; Yu HL; Sun HF; Wang JY; Lu X
Int J Oncol; 2020 Jan; 56(1):301-314. PubMed ID: 31746425
[TBL] [Abstract][Full Text] [Related]
2. High expression of SLC7A1 in high-grade serous ovarian cancer promotes tumor progression and is involved in MAPK/ERK pathway and EMT.
You S; Han X; Xu Y; Sui L; Song K; Yao Q
Cancer Med; 2024 May; 13(10):e7217. PubMed ID: 38752472
[TBL] [Abstract][Full Text] [Related]
3. The roles of FXYD family members in ovarian cancer: an integrated analysis by mining TCGA and GEO databases and functional validations.
Zhao E; Gao K; Xiong J; Liu Z; Chen Y; Yi L
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17269-17284. PubMed ID: 37814066
[TBL] [Abstract][Full Text] [Related]
4. TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer.
Lecker LSM; Berlato C; Maniati E; Delaine-Smith R; Pearce OMT; Heath O; Nichols SJ; Trevisan C; Novak M; McDermott J; Brenton JD; Cutillas PR; Rajeeve V; Hennino A; Drapkin R; Loessner D; Balkwill FR
Cancer Res; 2021 Nov; 81(22):5706-5719. PubMed ID: 34561272
[TBL] [Abstract][Full Text] [Related]
5. Redox processes inform multivariate transdifferentiation trajectories associated with TGFβ-induced epithelial-mesenchymal transition.
Prasanphanich AF; Arencibia CA; Kemp ML
Free Radic Biol Med; 2014 Nov; 76():1-13. PubMed ID: 25088330
[TBL] [Abstract][Full Text] [Related]
6. miR-1180 Targets FXYD5 to Regulate Pancreatic Cancer Cells Migration and Invasion.
Xie H; Li J; Lu M; Zhang R; Mao H
Mol Biotechnol; 2023 Dec; ():. PubMed ID: 38155284
[TBL] [Abstract][Full Text] [Related]
7. Notch3 signaling promotes tumor cell adhesion and progression in a murine epithelial ovarian cancer model.
Price JC; Azizi E; Naiche LA; Parvani JG; Shukla P; Kim S; Slack-Davis JK; Pe'er D; Kitajewski JK
PLoS One; 2020; 15(6):e0233962. PubMed ID: 32525899
[TBL] [Abstract][Full Text] [Related]
8. FXYD5 is a Marker for Poor Prognosis and a Potential Driver for Metastasis in Ovarian Carcinomas.
Raman P; Purwin T; Pestell R; Tozeren A
Cancer Inform; 2015; 14():113-9. PubMed ID: 26494976
[TBL] [Abstract][Full Text] [Related]
9. β-catenin/TCF4-induced SCUBE3 upregulation promotes ovarian cancer development via HIF-1 signaling pathway.
Shen J; Ma X; Wei Z; Qian Q; Jing A; Ding Y; Geng T; Qin J; Ma L; Chen Y; Ji J; Liu B; Huang J
Mol Cell Endocrinol; 2024 Mar; 582():112127. PubMed ID: 38109990
[TBL] [Abstract][Full Text] [Related]
10. Correction to: Dominant‑negative transforming growth factor‑β receptor‑armoured mesothelin‑targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer.
Li K; Xu J; Wang J; Lu C; Dai Y; Dai Q; Zhang W; Xu C; Wu S; Kang Y
Cancer Immunol Immunother; 2024 Apr; 73(6):105. PubMed ID: 38634982
[No Abstract] [Full Text] [Related]
11. The individualized significance of lymphadenectomy across all age groups and histologies in malignant ovarian germ cell tumors.
Wang J; Chen R; Li J; Lu X
Arch Gynecol Obstet; 2020 Dec; 302(6):1441-1450. PubMed ID: 32888090
[TBL] [Abstract][Full Text] [Related]
12. FXYD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness: Its Relationship With TGF-β1 and NF-κB Pathways.
Besso MJ; Rosso M; Lapyckyj L; Moiola CP; Matos ML; Mercogliano MF; Schillaci R; Reventos J; Colas E; Gil-Moreno A; Wernicke A; Orti R; Vazquez-Levin MH
Front Oncol; 2019; 9():1306. PubMed ID: 31867269
[No Abstract] [Full Text] [Related]
13. The prognostic value of ITGA and ITGB superfamily members in patients with high grade serous ovarian cancer.
Zhu T; Chen R; Wang J; Yue H; Lu X; Li J
Cancer Cell Int; 2020; 20():257. PubMed ID: 32565741
[TBL] [Abstract][Full Text] [Related]
14. Mucinous borderline ovarian tumors with and without Intraepithelial Carcinoma: Differences in clinicopathologic features and fertility results.
Chen RF; Tao X; Wu BB; Li J; Wang JY; Gu WY; Lu X
J Obstet Gynaecol Res; 2020 Apr; 46(4):646-653. PubMed ID: 32045956
[TBL] [Abstract][Full Text] [Related]
15. Gene signature characteristic of elevated stromal infiltration and activation is associated with increased risk of hematogenous and lymphatic metastasis in serous ovarian cancer.
Yue H; Wang J; Chen R; Hou X; Li J; Lu X
BMC Cancer; 2019 Dec; 19(1):1266. PubMed ID: 31888563
[TBL] [Abstract][Full Text] [Related]
16. Effect of differentiation, de novo innervation, and electrical pulse stimulation on mRNA and protein expression of Na+,K+-ATPase, FXYD1, and FXYD5 in cultured human skeletal muscle cells.
Jan V; Miš K; Nikolic N; Dolinar K; Petrič M; Bone A; Thoresen GH; Rustan AC; Marš T; Chibalin AV; Pirkmajer S
PLoS One; 2021; 16(2):e0247377. PubMed ID: 33635930
[TBL] [Abstract][Full Text] [Related]
17. Development and Clinical Validation of a Seven-Gene Prognostic Signature Based on Multiple Machine Learning Algorithms in Kidney Cancer.
Tian M; Wang T; Wang P
Cell Transplant; 2021; 30():963689720969176. PubMed ID: 33626918
[TBL] [Abstract][Full Text] [Related]
18. Low expression of FXYD5 reverses the cisplatin resistance of epithelial ovarian cancer cells.
Liu YK; Jia YJ; Liu SH; Shi HJ; Ma J
Histol Histopathol; 2021 May; 36(5):535-545. PubMed ID: 33570156
[TBL] [Abstract][Full Text] [Related]
19. Association analysis of FXYD5 with prognosis and immunological characteristics across pan-cancer.
Bai Y; Li L; Li J; Lu X
Heliyon; 2024 May; 10(9):e30727. PubMed ID: 38774095
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
